ipharmacenter Consulting services

Eli Lilly and Company has announced a major milestone in the development of its oral GLP-1 receptor agonist, orforglipron, following successful results from two large Phase 3 clinical studies—ACHIEVE-2 and ACHIEVE-5. These findings highlight orforglipron’s potential to become a foundational treatment for type 2 diabetes, offering both physicians and patients a new oral option in diabetes care. Key Study Highlights: In the ACHIEVE-2 trial, orforglipron lowered average HbA1c (a

Novo Nordisk, has taken a significant step in expanding its innovative portfolio by announcing the acquisition of Akero Therapeutics, a clinical-stage company specializing in treatments for serious metabolic diseases. This deal, valued at approximately $4.7 billion cash with a potential additional $0.5 billion pending regulatory approval, aims to enhance Novo Nordisk’s pipeline for metabolic dysfunction-associated steatohepatitis (MASH), one of the most rapidly growing obesit